Cd8a-IRES-DTRGFP

EGFP expression

Fig1.  Validation EGFP expression in PBMC by FACS.(Cooperation with CrownBio)

Validation data of DTR function

Heterozygous CD8a-IRES-DTRGFP mice and C57BL/6 mice were inoculated with MC38 colon cancer cells. After the tumors grew to 100 mm3, the CD8a-IRES-DTRGFP mice were injected with Diphtheria toxin. 

Fig2. The growth of MC38 tumors in Heterozygous CD8a-IRES-DTRGFP mice and C57BL/6 mice. (Cooperation with CrownBio)

Fig3. The percent of CD8+ T cell in peripheral blood of MC38 tumor-bearing CD8a-IRES-DTRGFP mice and C57BL/6 mice is detected by FACS. (Cooperation with CrownBio)

Fig4. The percent of CD8+ T cell in peripheral blood of MC38 tumor-bearing CD8a-IRES-DTRGFP mice and C57BL/6 mice is detected by FACS. Nearly complete depletion was  achieved only after 1 dose administration of DT and the depletion effect  lasted to day 14.(Cooperation with CrownBio)